Arcutis Q3 Revenue Jumps 45% to $143.9M, Full-Year Guidance Raised to $535-545M
ARQT sits 67% above its 52-week low of $19.295.
Summary
Arcutis posted Q3 2026 product revenue of $143.9 million (+45% year-over-year), net income of $8.8 million, and $18.9 million of operating cash flow, then raised full-year sales guidance to $535-545 million.
Key Events · Earnings and Guidance · ARQT
-
Q3 Revenue Grows 45% to $143.9M
Net product revenue of $143.9 million rose 45% from $99.2 million in Q3 2025 and 11% from Q2 2026, driven by unit demand across ZORYVE cream and foam.
-
Full-Year Guidance Raised
2026 net product sales guidance lifted to $535 million-$545 million from $525 million-$540 million, implying roughly $156-166 million in Q4.
-
Profitable and Cash Generative
Net income of $8.8 million ($0.06 diluted EPS) and $18.9 million of operating cash flow; cash, equivalents and marketable securities totaled $259.8 million at September 30, 2026.
-
SG&A Nearly Doubles Year-Over-Year
SG&A rose to $99.6 million from $62.4 million on the Skin to Believe In campaign and sales force expansion, while R&D rose to $22.4 million from $19.6 million.
Analysis · ARQT · Life Sciences
The story here is no longer about burn rate: Arcutis is now a profitable, cash-generating commercial company. Q3 product revenue of $143.9 million grew 45% year-over-year and 11% sequentially, net income was $8.8 million ($0.06 diluted EPS), and operations generated $18.9 million of cash, leaving $259.8 million in cash and marketable securities. Management raised full-year 2026 net product sales guidance to $535-545 million from $525-540 million, which implies roughly $156-166 million of Q4 revenue — a step up from Q3. The next hard catalyst is the FDA's February 23, 2027 target action date on ZORYVE cream 0.05% for infants 3-24 months, with vitiligo Phase 2 topline data due by year-end 2026. Spending is the offset: SG&A jumped to $99.6 million from $62.4 million a year ago on the celebrity awareness campaign and sales force expansion, so margin leverage depends on revenue outrunning that cost base.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARQT was trading at $32.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $19.30 to $34.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.